Volume 2.10 | Mar 18

Prostate Cell News 2.10, March 18, 2011.
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
TOP STORY
The IL-8 Regulated Chemokine Receptor CXCR7 Stimulates EGFR Signaling to Promote Prostate Cancer Growth
Here researchers report that the pro-cancerous cytokine IL-8 up regulates CXCR7 expression along with ligand-independent functions of CXCR7 that promote the growth and proliferation of human prostate cancer cells. [Cancer Res]

ALDEFLUORVideo_645x110_v01 
SPECIAL FEATURE

Webinar: ALDHbr Cells and Regenerative Medicine
Aldehyde Dehydrogenase bright (ALDHbr) cells have been used in preclinical models and human clinical trials in applications such as critical limb ischemia, ischemic stroke, acute liver failure and ischemic heart failure.1 Learn more about how ALDHbr cells could be used in regenerative medicine by registering today for an exclusive webinar presented by Dr. Andrew E. Balber of Cicada Biopharmaceutical Consulting.

Join us on April 7 at: 10AM EST (ideal for Europe) | 2PM EST (ideal for Americas) | 8PM EST (ideal for Asia-Pacific)

1 Reviewed in Balber AE. Stem Cells (in press). DOI: 10.1002/stem.613.
Dr. Balber holds equity in and is a consultant to Aldagen, Inc., a company that is developing research, diagnostic, and therapeutic products based on detecting and isolating ALDHbr cells.



social_default_facebook_icon.jpg “Like” Cell Therapy News on Facebook for a chance to win an Amazon gift card!

social_default_twitter_icon.jpg Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]
SCIENCE NEWS

Whitehead Scientist Helps Revisit “Hallmarks of Cancer”
Renowned cancer researchers Robert Weinberg and Douglas Hanahan have updated their seminal review, “Hallmarks of Cancer,” which has influenced the study of cancer and the development of therapeutics for more than a decade. [Press release from the Whitehead Institute for Biomedical Research discussing online prepublication in Cell]

Research Shows Rapid Adoption of Newer, More Expensive Prostate Cancer Treatments
New research shows that newer, more expensive treatment options for prostate cancer were adopted rapidly and widely during 2002 – 2005 without proof of their cost-effectiveness, and may offer explanations for why health care spending accounts for 17 percent of the nation’s GDP. [Press release from Brigham and Women’s Hospital discussing online prepublication in the Journal of Clinical Oncology]

Leading Scientists Unveil New Prostate Cancer Vaccine
Researchers presented findings from their studies with very promising results for the development and use of a new immunotherapeutic vaccine to treat patients with prostate cancer. [Press release from Innovative Minds in Prostate Cancer Today (IMPaCT) 2011 discussing data presented at the Prostate Cancer Research Program’s IMPaCT Conference]

Trial Treats Prostate Cancer with Diet
A new clinical trial will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer. [University of California, San Diego Press Release]

ON139-CTNSocialMedia_645x110

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Hallmarks of Cancer: The Next Generation
The hallmarks of cancer constitute an organizing principle for rationalizing the complexities of neoplastic disease. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list – reprogramming of energy metabolism and evading immune destruction. [Cell]

Genetic Ablation of PKC Epsilon Inhibits Prostate Cancer Development and Metastasis in Transgenic Mouse Model of Prostate Adenocarcinoma
Here scientists present the first in vivo genetic evidence that protein kinase C epsilon (PKCe) is essential for both the development and metastasis of prostate cancer in the transgenic mouse model of prostate adenocarcinoma (TRAMP). [Cancer Res]

Garlic Constituent Diallyl Trisulfide Suppresses X-Linked Inhibitor of Apoptosis Protein in Prostate Cancer Cells in Culture and In Vivo
The present study systematically investigates role of inhibitor of apoptosis family proteins in regulation of diallyl trisulfide (DATS)-induced apoptosis using cultured PC-3 and LNCaP human prostate cancer cells and dorsolateral prostate from control and DATS-treated Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice. [Cancer Prev Res]

Transgenic Expression of Polyoma Virus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma
In this study, investigators generated transgenic mice in which middle T is expressed in the mouse prostate under the control of an (ARR)2-Probasin promoter. [J Virol]

The Metastasis Suppressor, N-MYC Downstream Regulated Gene 1 (NDRG1), UP-Regulates P21 Via P53-Independent Mechanisms
The current study was focused on further elucidating the molecular mechanisms behind the anti-tumor function of NDGR1. [Carcinogenesis]

MiRNA Profiles of Prostate Carcinoma Detected by Multi-Platform miRNA Screening
To characterize the diagnostic potential of microRNAs (miRNAs) in prostate cancer, scientists performed screening of miRNA expression profiles. [Int J Cancer]

?-Tocotrienol Induces Apoptosis and Autophagy in Prostate Cancer Cells by Increasing Intracellular Dihydrosphingosine and Dihydroceramide
Here researchers showed that ?-tocotrienol treatment promoted apoptosis, necrosis and autophagy in human prostate PC-3 and LNCaP cancer cells. [Int J Cancer]

High-Level Expression of Forkhead-Box Protein A1 in Metastatic Prostate Cancer
The aim of this study was to investigate the expression and potential role of forkhead-box protein A1 and GATA3 transcription factors as prognostic factors in prostate cancer. [Histopathology]

CLINICAL RESEARCH

Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer
Using Surveillance, Epidemiology, and End Results–Medicare linked data, investigators determined treatment patterns for 45,636 men age 65 years or older who received definitive surgery or radiation for localized prostate cancer diagnosed from 2002 to 2005. [J Clin Oncol]

Serum Retinol and Risk of Prostate Cancer
The authors prospectively examined prostate cancer risk and serum retinol levels, measured by using high-performance liquid chromatography, at baseline (n = 29,104) and after 3 years (n = 22,843) in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort. [Am J Epidemiol]

Impact of Androgen Deprivation on Physical Well-Being in Patients with Prostate Cancer: Analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) Registry
In this study, the authors evaluated the effect of androgen deprivation therapy administered as monotherapy and in combination with local treatment on physical well-being in a longitudinal sample of men with prostate cancer. [Cancer]

Cysteine-Rich Secretory Protein 3 and ß-Microseminoprotein on Prostate Cancer Needle Biopsies Do Not Have Predictive Value for Subsequent Prostatectomy Outcome
To investigate whether cysteine-rich secretory protein 3 and/or ß-microseminoprotein expression in diagnostic prostate needle biopsies have predictive value for prostate cancer on radical prostatecomy. [BJU Int]

INDUSTRY NEWS

Six From Health Science Center Win AACR Cancer Research Awards
Six investigators from The University of Texas Health Science Center San Antonio will receive awards from the American Association for Cancer Research (AACR) at its annual meeting. [The University of Texas Health Science Center San Antonio Press Release]

Hospira Announces U.S. Approval of Generic Docetaxel
Hospira, Inc. announced U.S. Food and Drug Administration approval of docetaxel. The medication is a generic version of Sanofi-Aventis’s Taxotere®, and Hospira expects to launch the product later this month. [Hospira, Inc. Press Release]

MD Anderson and the National Cancer Institute of Peru and Sign Sister Institution Agreement in Cancer Treatment and Research
The University of Texas MD Anderson Cancer Center signed a sister institution agreement with the National Cancer Institute of Peru. The agreement formalizes plans to collaborate on groundbreaking achievements in cancer research and care that will benefit patients in the United States, Latin America and around the world. [The University of Texas MD Anderson Cancer Center Press Release]

NextGen Sciences Launches Multiple Protein Plasma Oncology Biomarker Assay
NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc. has launched its first multiple protein (multiplex) assay, plasmadiscovery41, for oncology biomarker discovery and qualification. [NextGen Group plc Press Release]

New Drugs for Prostate Cancer
Thanks to a £179,532 grant, Dr Cynthia K Miranti will investigate the mechanism that controls alterations in cells in the prostate gland and the possibility that prostate cancer arises because of some form of mistaken change happening to these cells. [Association for International Cancer Research Press Release]

POLICY NEWS

Pentagon Cancer Research Budget Comes Under Scrutiny
As the Pentagon seeks to trim spending, there are some programs Congress believes the military can’t do without. Among them: cancer research. [Congress, United States]

Active Surveillance Monitoring More Stringent in Updated NCCN Guidelines for Prostate Cancer
Active surveillance or immediate treatment? The question that many men with prostate cancer and their clinicians struggle with continues to be a focus in the updated NCCN Guidelines™ for Prostate Cancer. [National Comprehensive Cancer Network (NCCN), United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW BIT’s 4th Annual World Cancer Congress 2011
May 22-25, 2011
Dalian, China 

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES
Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Cell Processing Associates (Kelly Scientific Resources)

Prostate Cancer Computational Biology Team Lead (Ontario Institute for Cancer Research)

Post-doctoral Position Metastasis Research Laboratory (University of Liege)

Postdoctoral Fellow (University of Houston – Center for Nuclear Receptors and Cell Signaling)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us